New drug trial targets rare, debilitating protein disease

NCT ID NCT06158854

Recruiting now Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

Summary

This study is testing an experimental drug called etentamig (ABBV-383) for adults with AL amyloidosis, a rare disease where abnormal proteins damage organs. The trial aims to find a safe and effective dose and see if the drug can reduce disease markers in the blood and improve organ function. About 76 participants whose disease has returned or not responded to prior treatments will receive intravenous infusions for up to two years.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IMMUNOGLOBULIN LIGHT CHAIN (AL) AMYLOIDOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Alexandra General Hospital /ID# 255542
RECRUITING

Athens, Attica, 11528, Greece
Atrium Health Levine Cancer Institute /ID# 255074
RECRUITING

Charlotte, North Carolina, 28204, United States
Atrium Health Wake Forest Baptist Medical Center /ID# 255851
RECRUITING

Winston-Salem, North Carolina, 27157, United States
Boston Medical Center /ID# 255066
RECRUITING

Boston, Massachusetts, 02118, United States
Box Hill Hospital /ID# 255199
RECRUITING

Box Hill, Victoria, 3128, Australia
CHU Limoges - Dupuytren 1 /ID# 255370
RECRUITING

Limoges, Franche-Comte, 87042, France
CHU Toulouse - Hopital Rangueil /ID# 255377
RECRUITING

Toulouse, Haute-Garonne, 31400, France
Columbia University Medical Center /ID# 255068
RECRUITING

New York, New York, 10032-3729, United States
IRCCS AOU di Bologna Policlinico Sant Orsola Malpighi /ID# 255654
RECRUITING

Bologna, 40138, Italy
Icahn School of Medicine at Mount Sinai /ID# 255408
RECRUITING

New York, New York, 10029, United States
Japanese Red Cross Medical Center /ID# 256083
RECRUITING

Shibuya-ku, Tokyo, 150-8935, Japan
Kumamoto University Hospital /ID# 262579
RECRUITING

Kumamoto, Kumamoto, 8608556, Japan

Contact Phone: •••-•••-••••
Mayo Clinic - Rochester /ID# 255258
RECRUITING

Rochester, Minnesota, 55905-0001, United States
Memorial Sloan Kettering Cancer Center-Koch Center /ID# 255073
RECRUITING

New York, New York, 10065-6007, United States
Nagoya City University Hospital /ID# 256086
RECRUITING

Nagoya, Aichi-ken, 467-8602, Japan
Oregon Medical Research Center /ID# 255119
RECRUITING

Portland, Oregon, 97239, United States
Princess Alexandra Hospital /ID# 255202
RECRUITING

Woolloongabba, Queensland, 4102, Australia
Sylvester Comprehensive Cancer Center - University of Miami /ID# 255856
RECRUITING

Miami, Florida, 33136, United States
University of Washington /ID# 261581
RECRUITING

Seattle, Washington, 98109, United States
Westmead Hospital /ID# 255200
RECRUITING

Westmead, New South Wales, 2145, Australia
Wisconsin Medical Center /ID# 255836
RECRUITING

Milwaukee, Wisconsin, 53226, United States

Conditions

Explore the condition pages connected to this study.

IMMUNOGLOBULIN LIGHT CHAIN (AL) AMYLOIDOSIS